Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at Mizuho

Stock analysts at Mizuho assumed coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a report issued on Monday, The Fly reports. The firm set a “neutral” rating on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the stock. Wedbush boosted their price objective on shares of Audentes Therapeutics to $56.00 and gave the company an “outperform” rating in a report on Thursday, January 4th. HC Wainwright set a $37.00 price objective on shares of Audentes Therapeutics and gave the company a “buy” rating in a report on Thursday, January 4th. BMO Capital Markets set a $44.00 target price on shares of Audentes Therapeutics and gave the company a “buy” rating in a report on Friday, January 5th. William Blair started coverage on shares of Audentes Therapeutics in a report on Tuesday, October 17th. They set an “outperform” rating and a $35.00 target price for the company. Finally, ValuEngine cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Audentes Therapeutics has a consensus rating of “Buy” and an average target price of $35.00.

Audentes Therapeutics (BOLD) traded up $1.47 on Monday, hitting $32.80. 215,757 shares of the stock traded hands, compared to its average volume of 575,381. Audentes Therapeutics has a 1 year low of $13.90 and a 1 year high of $41.80. The stock has a market capitalization of $1,138.73, a PE ratio of -9.40 and a beta of 0.41.

In other Audentes Therapeutics news, SVP Mary Newman sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $26.84, for a total transaction of $268,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total transaction of $555,840.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 36,000 shares of company stock valued at $1,052,480. 47.30% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in BOLD. SG Americas Securities LLC bought a new position in shares of Audentes Therapeutics in the third quarter worth approximately $143,000. Nationwide Fund Advisors boosted its position in shares of Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 6,384 shares during the period. Wells Fargo & Company MN boosted its position in shares of Audentes Therapeutics by 86.1% in the third quarter. Wells Fargo & Company MN now owns 14,414 shares of the biotechnology company’s stock worth $404,000 after purchasing an additional 6,667 shares during the period. Teacher Retirement System of Texas bought a new position in shares of Audentes Therapeutics in the fourth quarter worth approximately $208,000. Finally, Ardsley Advisory Partners boosted its position in shares of Audentes Therapeutics by 59.7% in the second quarter. Ardsley Advisory Partners now owns 20,072 shares of the biotechnology company’s stock worth $384,000 after purchasing an additional 7,500 shares during the period. 64.94% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/12/audentes-therapeutics-bold-coverage-initiated-by-analysts-at-mizuho.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

The Fly

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply